ADG116

DRUG3 trials

Sponsors

Adagene Inc

Conditions

Advanced/Metastatic Solid TumorsSolid Tumor

Phase 1

Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

TerminatedNCT04111445

Adagene IncSolid Tumor

Start: 2019-08-29End: 2021-04-27Updated: 2021-09-10

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

CompletedNCT04501276

Adagene IncAdvanced/Metastatic Solid Tumors

Start: 2020-09-23End: 2025-11-30Updated: 2026-01-08

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

CompletedNCT05277402

Adagene IncAdvanced/Metastatic Solid Tumors

Start: 2022-02-09End: 2022-12-01Updated: 2024-02-26

Related Papers

753 A phase 1b/2 study of a novel anti-CTLA-4 NEObody<sup>TM</sup> ADG116 monotherapy and in combination with toripalimab (Tori; Anti-PD-1 Antibody) in patients with advanced/metastatic solid tumors

Regular and Young Investigator Award Abstracts2022-11-01

773 A phase 1b/2, open-label, dose escalation and expansion study of an anti-CTLA-4 NEOBody<sup>TM</sup> ADG116 in combination with pembrolizumab (anti-PD-1 antibody) in patients with advanced/metastatic solid tumors: a preliminary update

Regular and Young Investigator Award Abstracts2022-11-01

Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T<sub>reg</sub> depletion and soft ligand blocking in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-01